Immatics (IMTX) Prix de l'Action, Cotation, Actualités et Historique | Benzinga

Immatics NV (IMTX) Prix de l'Action, Cotation, Actualités et Historique

IMTXNASDAQ

Trade with Public

Trade with Public

$7.05

0.324.75%

Dern. MÀJ: Oct 19, 4:00 PM

$7.05

0.324.75%

AperçuActualités Prévisions de résultats Événements Objectifs de cours Données financières Sentiment Actionnariat Comparer Options Rapport sur les stocks

© 2026 Benzinga | All Rights Reserved

Statistiques Clés

Ouverture

$6.85

Clôture

$7.05

Volume / Moy.

967.07K / 666.98K

Fourchette Journalière

$6.72 - $7.20

Plage 52 Sem.

6.73 - 12.41

Capitalisation Boursière

$1.07B

Ratio P/E

-

Rendement des Dividendes

-

Échange

NASDAQ

RSI

40

Intérêt à Découvert

3.36%

Jours pour Couvrir

4.15

Actualités Récentes de Immatics N.V.

This Entegris Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Analysts initiated coverage on VYLR, IMTX, ENTG, SLGL and SPTX, assigning Neutral, Buy or Overweight ratings and price targets.

Avi Kapoor

Nayax, Immatics, Moderna, Marvell Technology And Other Big Stocks Moving Higher On Tuesday

Nasdaq: NYAX rose 13.9% on Tuesday after announcing acquisition of IPS Group Inc. for $350 million. Other big gainers include CAPR, RZLV, CRML, and MAIR.

Avi Kapoor

Fabrinet, Adecoagro And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Avi Kapoor

Why Is Cancer-Focused Immatics Stock Trading Lower On Thursday?

Immatics announced updated Phase 1b data for its IMA203 therapy in metastatic melanoma. A deep tumor reduction response was observed in about half of the patients, with positive survival benefits shown. Phase 3 trials are set to begin by December 2024.

Vandana Singh

AstraZeneca Imfinzi Combo Gets EU Nod for Uterine Cancer

AstraZeneca (NASDAQ: AZN) announced that the combination therapy of its PD-L1 inhibitor, Imfinzi (durvalumab), and PARP inhibitor, Lynparza (olaparib), has been approved in the EU to treat certain patients with primary advanced or recurrent endometrial cancer, also known as uterine cancer.

Zacks

Données financières

Trimestriel

Annuel

Nom

Revenu Changement
Brut Changement
EBITDA Changement
EBIT Changement
Bénéfices Changement

Flux de Trésorerie

Flux de Trésorerie Opérationnel (TTM)

-205.87M

Flux de Trésorerie d'Investissement (TTM)

57.49M

Flux de Trésorerie de Financement (TTM)

119.12M

Flux de Trésorerie Libre (TTM)

-209.62M

Dépenses en Capital (TTM)

-3.75M

Variation Nette de la Trésorerie (TTM)

-29.25M

Tendances et prévisions des analystes

1

avr.

1

mai

1

oct.

Acheter

Conserver

Vendre

Vente forte

Évaluation et prévisions des analystes

4.2

Acheter

Achat fort

Acheter

Conserver

Vendre

Vente forte

Métriques de Valorisation

Valeur Entreprise

$599.80M

Ratio P/E (TTM)

-

Ratio P/E (FWD)

-

Ratio PEG (TTM)

-

Ratio P/S (TTM)

18.65

Ratio P/B (TTM)

2.29

Rendement des Bénéfices % (TTM)

-26.45%

Rendement des Bénéfices % (FWD)

-32.76%

EV / EBITDA (TTM)

-

Prix / EBITDA (TTM)

-

Prix / Flux de Trésorerie Libre (TTM)

-

Valeur Comptable / Action

$2.94

Dette Entreprise

Dette Totale

-

Dette à Long Terme

-

Émission de Dette à Long Terme (TTM)

-

Remboursement de la Dette à Long Terme (TTM)

-$2.97M

Trésorerie Totale

$232.46M

Dette sur Capitaux Propres

0.04

Émission de Dette (TTM)

-$2.97M

Remboursement de la Dette (TTM)

-$2.97M